지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.97 No.2
- 발행연도
- 2019.8
- 수록면
- 93 - 102 (10page)
이용수
초록· 키워드
오류제보하기
Purpose: ATP-based chemotherapy response assay (ATP-CRA) is a well-documented and validated technology that can individualize chemotherapy. This study was undertaken to assess the usefulness of ATP-CRA in advanced colorectal cancer (CRC) patients receiving adjuvant chemotherapy.
Methods: A total of 136 patients with curative resection between January 2006 and April 2014 were evaluated using ATPCRA. Patients received either the FOLFOX or Mayo clinic regimen chemotherapy following assay results. The sensitivegroup (S-group) was defined as a drug-producing ≥ 40% reduction in ATP, and the resistant-group (R-group) as an ATP reduction of ＜ 40%. These 2 groups were further subdivided to produce 4 subgroups: the FOLFOX sensitive subgroup (the FS subgroup [n = 65]), the Mayo sensitive subgroup (the MS subgroup [n = 40]), the FOLFOX resistant subgroup (the FR subgroup [n = 10]), and the Mayo resistant subgroup (the MR subgroup [n = 21]). Clinical responses and survival results were compared for both treatment regimens.
Results: The FS and MS subgroups showed a better disease-free survival rate (29% vs. 40%, 35% vs. 47.6%) and overall survival rate (92.3% vs. 80.0%, 87.5% vs. 76.2%) than FR and MR subgroups. The FS and MS subgroups showed a longer time to relapse (20.2 months vs. 9.5 months, 17.6 months vs. 16.4 months) than the FR and MR subgroups.
Conclusion: ATP-CRA tailored-chemotherapy has the potential to provide a survival benefit in resectable advanced CRC.
Methods: A total of 136 patients with curative resection between January 2006 and April 2014 were evaluated using ATPCRA. Patients received either the FOLFOX or Mayo clinic regimen chemotherapy following assay results. The sensitivegroup (S-group) was defined as a drug-producing ≥ 40% reduction in ATP, and the resistant-group (R-group) as an ATP reduction of ＜ 40%. These 2 groups were further subdivided to produce 4 subgroups: the FOLFOX sensitive subgroup (the FS subgroup [n = 65]), the Mayo sensitive subgroup (the MS subgroup [n = 40]), the FOLFOX resistant subgroup (the FR subgroup [n = 10]), and the Mayo resistant subgroup (the MR subgroup [n = 21]). Clinical responses and survival results were compared for both treatment regimens.
Results: The FS and MS subgroups showed a better disease-free survival rate (29% vs. 40%, 35% vs. 47.6%) and overall survival rate (92.3% vs. 80.0%, 87.5% vs. 76.2%) than FR and MR subgroups. The FS and MS subgroups showed a longer time to relapse (20.2 months vs. 9.5 months, 17.6 months vs. 16.4 months) than the FR and MR subgroups.
Conclusion: ATP-CRA tailored-chemotherapy has the potential to provide a survival benefit in resectable advanced CRC.
목차
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
Cancer Research and Treatment
2016 .01
-
Guideline of Adjuvant Chemotherapy - Colorectal Cancer
대한외과학회 학술대회 초록집
2017 .11
-
전이성대장암환자에서 체외 항암약물 감수성 검사와 일차항암화학요법 간의 임상적 연관성
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2015 .12
-
[Colorectal] What is the Role of Adjuvant Chemotherapy in Elderly Patients with Colorectal Cancer?
대한외과학회 학술대회 초록집
2022 .11
-
The efficacy of chemotherapy in the patients with stage II colon cancer associated with number of high-risk factors
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study
Journal of Gastric Cancer
2015 .01
-
Chemotherapy : Is it needed?
대한외과학회 학술대회 초록집
2015 .11
-
Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage Ⅲ colon cancer
Annals of Surgical Treatment and Research
2015 .08
-
Adjuvant chemotherapy for patients with stage II high-risk and III colon cancer: Hindering factors to adherence and impact on long-term survival
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2021 .06
-
Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
Annals of Surgical Treatment and Research
2018 .04
-
Early Initiation and Reduced Cycles of Adjuvant Chemotherapy [FOLFOX4] after Minimally Invasive Colorectal Cancer Surgery in Elderly Patient
대한임상종양학회 학술대회지
2016 .02
-
Adjuvant Chemotherapy
대한외과학회 학술대회 초록집
2021 .11
-
Quality of life changes during adjuvant chemotherapy in patients with colon cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2016 .06
-
Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
Journal of Breast Cancer
2015 .01
-
췌장 및 담도암 환자의 항암 시작, 반응 평가 및 항암 중단 시점
대한췌담도학회지
2020 .01
-
Changes of Cognitive Function and Fatigue following Chemotherapy in Patients with Gastrointestinal Cancer: A Prospective Controlled Study
Asian Oncology Nursing
2019 .09
-
Effects of 7~11 cycles adjuvant FOLFOX chemotherapy on the prognosis of patients with stage III colon cancer
의생명과학
2019 .01
-
Expansion of surgeon"s role in chemotherapy for colorectal cancer
대한임상종양학회 학술대회지
2022 .02
-
Comparison between neoadjuvant chemotherapy and upfront surgery for patients with resectable and synchronous colorectal cancer hepatic metastases
대한임상종양학회 학술대회지
2019 .02
-
Effect of age on laparoscopic surgery and adjuvant chemotherapy in elderly colorectal cancer patients
대한외과학회 학술대회 초록집
2019 .10
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2019-514-000942490